Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omadacycline vs Standard-of-Care for Bone and Joint Infections
NCT05753215Phase 2Active, not recruiting
- Sponsor
- The Lundquist Institute
- Start
- May 2023
- Primary completion
- Feb 2026
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of omadacycline in Bone and osteoarticular infections (BJI), sponsored by The Lundquist Institute. Started May 2023; status: active, not recruiting.
02
Drugs
omadacycline
03
Conditions
Bone and osteoarticular infections (BJI)
Beyond the preview
Go deeper on NCT05753215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05753215.